Estimated prevalence and distribution of causes of immune-mediated hypertrophic pachymeningitis in São Paulo, Brazil - Top-Institutions - MDSpire

Estimated prevalence and distribution of causes of immune-mediated hypertrophic pachymeningitis in São Paulo, Brazil

  • By

  • Daniela Ohlweiler Brescovit

  • Sara Terrim

  • Graziela Aguiar Santos Faria

  • Vitor Falcão de Oliveira

  • Tarso Adoni

  • Suely Kazue Nagahashi Marie

  • Luiz Henrique Martins Castro

  • Guilherme Diogo Silva

  • July 15, 2026

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
    Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo

    São Paulo, SP

    Key Differentiators

    • Neurology

  • #2

    Federal University of São Paulo (UNIFESP)
    Federal University of São Paulo (UNIFESP)

    São Paulo, SP

    Key Differentiators

    • Neurology

  • #3

    Hannover Medical School
    Hannover Medical School

    Hannover, Lower Saxony

    Key Differentiators

    • Neurology

  • #4

    Skåne County Hospitals
    Skåne County Hospitals

    Lund, Skåne

    Key Differentiators

    • Neurology

  • #5

    University of Würzburg
    University of Würzburg

    Würzburg, Bavaria

    Key Differentiators

    • Neurology

Original Source(s)

Estimated prevalence and distribution of causes of immune-mediated hypertrophic pachymeningitis in São Paulo, Brazil

  • by Daniela Ohlweiler Brescovit, Sara Terrim, Graziela Aguiar Santos Faria, Vitor Falcão de Oliveira, Tarso Adoni, Suely Kazue Nagahashi Marie, Luiz Henrique Martins Castro, Guilherme Diogo Silva

  • July 15, 2026

Related Content

Thyroid autoimmunity and spontaneous cervicocranial artery dissection: an exploratory segment-specific case-control study

Developmental neurotoxicity of atrazine: decreased synaptic spine density and miRNA-driven GluN2A downregulation in primary hippocampal neurons

Interpretable machine learning-driven multi-omics risk stratification and drug repurposing nominates Treg/Th17 with gluconeogenesis/lactylation integration as a prognostic and druggable biomarker for glioblastoma patients